PMDA Adds May 2026 Data to Suspected Adverse Case Reports for Regenerative Medical Products
「不具合が疑われる症例報告に関する情報（再生医療等製品）」に2026年5月分の情報を追加しました
Published: 2026-09-25 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Medium · First detected by this dashboard: 2026-09-26
View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard
AI summary
Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.
Summary
The Pharmaceuticals and Medical Devices Agency (PMDA) announced that it has added information for May 2026 to its collection of suspected adverse (defect-related) case reports concerning regenerative medicine and similar products. This is a routine safety update posted under the PMDA safety operations section. The details of the added reports are not provided in the metadata.
Business Impact
Organizations dealing with regenerative medical products may wish to consider whether the updated case report data is relevant to their safety monitoring or reporting activities.
Recommended Action
Review the official PMDA source page to confirm the specific contents and scope of the newly added case report information.